Received Mar 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | — |
A HCP (pharmacist) called to inquire about whether the GARDASIL 9 vaccine was indicated for use in women greater than 45 years of age. The HCP stated she had a 62 or 63 year old consumer/patient presently at the pharmacy who requested to receive her; No additional AE.; This spontaneous report was received from a Pharmacist and refers to an Adult (62 or 63 year old) female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 03-SEP-2024, the patient was vaccinated with the first dose of human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (strength, dose, route, lot #, expiration date and anatomical location were not provided), then on 04-NOV-2024, the patient received the second dose of human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (strength, dose, route, lot #, expiration date and anatomical location were not provided) for prophylaxis (Inappropriate age at vaccine administration). The patient presented at the pharmacy who requested to receive her third dose of human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) vaccine on 07-MAR-2025. No adverse event reported. It was also mentioned that the patient had an article with her that recommended healthcare workers who had been exposed to "fumes" should get the human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) vaccine to prevent throat cancer (captured in case#: 2263369)